European ScreeningPort and Merck KGaA Sign Research Agreement
News Oct 28, 2010
European ScreeningPort GmbH has announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, as part of the New Drugs Fighting Neurological Diseases Consortium (NEU²).
Under the agreement, the European ScreeningPort will use its expertise in order to establish a high-throughput screening assay for a target implicated in multiple sclerosis. This will involve the evaluation of a variety of biochemical and cellular assay formats. Ultimately, it is envisaged that an appropriate high-throughput screening assay can be developed, which can be employed in a small molecule screening campaign to identify starting points for drug discovery.
Multiple sclerosis is one of the most widespread neurological diseases in young adults estimated to affect approximately 2 million people worldwide. The symptoms, onset and progression of these diseases are heterogeneous and their treatment is limited to using disease modifying drugs (DMDs) aiming towards improving the patient's quality of life.
Prof Carsten Claussen, Managing Director comments: "This agreement represents another step forward for the European ScreeningPort being attractive also for the Pharmaceutical industry within new set ups between organizations like us, Academics and the Industry. We will contribute to this project with our expertise and highly flexible approach to challenging projects with the ultimate goal to develop innovative therapies for multiple sclerosis.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE